Background: Sarcopenia, which has traditionally been considered to be an exclusively geriatric syndrome, has an increased frequency within the general population and fosters interest in its complex neuromuscular, cardiovascular, and metabolic basis. The current systematic review, adopting the recognized Preferred Reporting Items for Systematic Reviews (PRISMA) methodology, seeks to highlight current evidence on the underlying mechanisms as well as approaches to sarcopenia diagnosis and management. Methods: A comprehensive search of major international databases identified studies published between January 2023 and December 2024, from which 42 articles were retained according to prespecified criteria. To further enrich the present work, eleven additional studies of high relevance were included. Results: The selected literature describes sarcopenia’s multifactorial pathophysiology, including mitochondrial dysfunction, neuromuscular junction (NMJ) degeneration, chronic inflammation, anabolic resistance, endocrine and metabolic dysregulation, altered motor-unit remodeling, and molecular alterations. Diagnostic methods focus on functional assessments, especially muscle strength and physical performance. In addition, imaging techniques and new circulating biomarkers enhance precision in specific situations. Over the years, rehabilitation has proven to be one of the most effective therapeutic approaches. Complementary strategies, ranging from nutritional optimization to pharmacologic modulation of the renin–angiotensin system, show promise in specific patient subsets. Discussion and Conclusions: As supported by the works collected within the current study, future approaches will need to consider sarcopenia as a multifactorial disease that goes beyond aging.

Background: Nutriepigenetics, the study of nutritional effects on gene expression, offers new insights into the clinical variability and relapse frequency of inflammatory bowel disease (IBD). As older adult populations are frequently unrepresented in the literature regarding their nutrition’s influence on their gene expression, we considered that studying this aspect would shed light on this population group. Materials and Methods: We conducted a prospective observational study on 60 IBD patients, categorized by age, residence, and nutrition access. Patients were grouped according to age groups (“young”-old—65–74 years old and old-old—75–86 years old), gender, IBD type, organic diet preference, Simple Clinical Colitis Activity Index (SCCAI), and Harvey-Bradshaw Index (HBI) at diagnosis and after diet change. All patients were followed up at the Fundeni Clinical Institute in Bucharest, Romania, and received personalized dietary recommendations, in accordance with the European guidelines. Results: Our findings revealed that a diet that was predominantly organic had a positive impact on decreasing the number of relapse episodes, irrespective of IBD type. Predominant diets, rich in dairy and saturated fats, mostly from non-organic sources, exacerbated inflammation and increased the frequencies of relapses. Conclusions: Older adult patients who adopted a predominantly organic diet had a reduction in frequency of relapse episodes, thus proving that diet is an important part of the treatment regimen of this population.

Background and Objectives: A degenerative joint disease that primarily affects the elderly, osteoarthritis (OA) causes pain, decreased mobility, and a lower quality of life. The effectiveness of GerovitalH3, a biotrophic medication created by Ana Aslan, in reducing pain and enhancing function in older people with osteoarthritis in the knee and hip is assessed in this study. Materials and Methods: Two groups of 201 patients aged 65 and older participated in a randomized, case-control clinical trial. One group received physical therapy and GerovitalH3 periarticular injections, while the other group received just physical therapy. In addition to functional evaluations using the Lequesne Index, Activities of Daily Living (ADL), and Instrumental ADL (IADL) scores, pain was assessed using a Visual Analogue Scale (VAS). Results: The GerovitalH3 group showed a substantial decrease in pain (p<0.001) and an improvement in daily activities (p<0.001) when compared to the control group. However, there was no significant difference in walking scores (p = 0.171). There were no significant adverse effects noted. GerovitalH3 did not outperform physical therapy for reducing depression, even though both groups displayed some improvement in this area. Conclusions: This study opens a new possibility for periarticular injections of Gerovital H3 treatment combined with physical therapy, which may represent a safe and effective non-surgical option for elderly individuals struggling with OA pain and functional limitations. The findings of this study reinforce the need for further research, particularly randomized controlled trials with larger sample sizes and longer follow-up periods.